Key statistics
As of last trade Nuvectis Pharma Inc (NVCT:NAQ) traded at 8.78, -23.83% below its 52-week high of 11.52, set on Apr 28, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.67 |
|---|---|
| High | 8.89 |
| Low | 8.47 |
| Bid | 8.77 |
| Offer | 8.88 |
| Previous close | 8.76 |
| Average volume | 78.54k |
|---|---|
| Shares outstanding | 26.49m |
| Free float | 15.47m |
| P/E (TTM) | -- |
| Market cap | 232.07m USD |
| EPS (TTM) | -1.31 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 17:13 GMT.
More ▼
- Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
- Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
- Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
- Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
- Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
- Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
- Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
- Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
More ▼
